Show simple item record

dc.contributor.authorGranslo, Hildegunn Norbakken
dc.contributor.authorAarag, Elizabeth
dc.contributor.authorEsaiassen, Eirin
dc.contributor.authorChristophersen, Lars
dc.contributor.authorJensen, Peter Østrup
dc.contributor.authorMollnes, Tom Eirik
dc.contributor.authorMoser, Claus
dc.contributor.authorFlægstad, Trond
dc.contributor.authorKlingenberg, Claus
dc.contributor.authorCavanagh, Jorunn Pauline
dc.date.accessioned2020-01-27T14:43:34Z
dc.date.available2020-01-27T14:43:34Z
dc.date.issued2019-03-27
dc.description.abstractThe global spread of antimicrobial resistance and the increasing number of immune‐compromised patients are major challenges in modern medicine. Targeting bacterial virulence or the human host immune system to increase host defence are important strategies in the search for novel antimicrobial drugs. We investigated the inflammatory response of the synthetic short antimicrobial peptide LTX21 in two model systems: a human whole blood <i>ex vivo</i> model and a murine <i>in vivo</i> peritoneum model – both reflecting early innate immune response. In the whole blood model, LTX21 increased the secretion of a range of different cytokines, decreased the level of tumour necrosis factor (TNF) and activated the complement system. In a haemolysis assay, we found 2.5% haemolysis at a LTX21 concentration of 500 mg/L. In the murine model, increased influx of white blood cells (WBCs) and polymorphonuclear neutrophils (PMNs) in the murine peritoneal cavity was observed after treatment with LTX21. In addition, LTX21 increased monocyte chemoattractant protein‐1 (MCP‐1). In conclusion, LTX21 affected the inflammatory response; the increase in cytokine secretion, complement activation and WBC influx indicates an activated inflammatory response. The present results indicate the impact of LTX21 on the host–pathogen interplay. Whether this will also affect the course of infection has to be investigated.en_US
dc.description<p>This is the peer reviewed version of the following article: Granslo, H.N., Aarag Fredheim, E.G., Esaiassen, E., Christophersen, L., Jensen, P.Ø., Mollnes, T.E., ... Cavanagh, J.P. (2019). The synthetic antimicrobial peptide LTX21 induces inflammatory responses in a human whole blood model and a murine peritoneum model. <i>APMIS, 127</i>, 475– 483, which has been published in final form at <a href=https://doi.org/10.1111/apm.12946>https://doi.org/10.1111/apm.12946</a>. This article may be used for non-commercial purposes in accordance with Wiley <a href=https://authorservices.wiley.com/author-resources/Journal-Authors/licensing/self-archiving.html>Terms and Conditions for Use of Self-Archived Versions</a>.en_US
dc.identifier.citationGranslo, H.N., Aarag Fredheim, E.G., Esaiassen, E., Christophersen, L., Jensen, P.Ø., Mollnes, T.E., ... Cavanagh, J.P. (2019). The synthetic antimicrobial peptide LTX21 induces inflammatory responses in a human whole blood model and a murine peritoneum model. <i>APMIS, 127</i>, 475– 483. https://doi.org/10.1111/apm.12946en_US
dc.identifier.cristinIDFRIDAID 1707961
dc.identifier.doi10.1111/apm.12946
dc.identifier.issn0903-4641
dc.identifier.issn1600-0463
dc.identifier.urihttps://hdl.handle.net/10037/17232
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.journalActa Pathologica, Microbiologica et Immunologica Scandinavica (APMIS)
dc.rights.accessRightsopenAccessen_US
dc.rights.holder© 2019 APMISen_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Communicable diseases: 776en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Infeksjonsmedisin: 776en_US
dc.titleThe synthetic antimicrobial peptide LTX21 induces inflammatory responses in a human whole blood model and a murine peritoneum modelen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record